StockMirror — Stock Screener

SENORES Q1 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Senores Pharmaceuticals delivered a strong Q1 FY27 with revenue up 36% YoY, EBITDA up 87% YoY, and PAT up 56% YoY, supported by robust growth in both regulated and emerging markets. Management provided a confident FY27 guidance of 30-40% revenue growth and 50-60% PAT growth, with a long-term target of INR2,500-3,000 crores in 3-4 years. However, sequential margin dilution in emerging markets and questions around strategic capital allocation warrant monitoring.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management highlighted strong growth (~30-40% revenue) while maintaining and improving EBITDA margins (up 810 bps YoY), with a focus on operational excellence and profitable growth

About Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited (SENORES) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More